SCHEMBL3782855

SCHEMBL3782855

CCc1cnc(NC2CCN(C(=O)OC(C)(C)C)CC2)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.52
NPC1 O15118 1/20 0.52
MAPT P10636 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
RAB9A P51151 1/20 0.52
EPHX1 P07099 1/20 0.47
CDK12 Q9NYV4 1/20 0.47
GPR119 Q8TDV5 4/20 0.46
JAK1 P23458 1/20 0.46
USP30 Q70CQ3 1/20 0.45
IDH1 O75874 1/20 0.45
IDH2 P48735 1/20 0.45
NOS2 P35228 1/20 0.45
DNMT3A Q9Y6K1 1/20 0.44
ADORA2A P29274 1/20 0.44
CDK1 P06493 1/20 0.44
CDK4 P11802 1/20 0.44
CCND1 P24385 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773857 0.86 NOS2 (0.59) ALDH1A1L3MBTL1MAPTHTTCDK12
SCHEMBL30914985 0.86 ALDH1A1 (0.56) ALDH1A1L3MBTL1NPC1MAPTMAPK1
SCHEMBL3769585 0.86 ALDH1A1 (0.56) ALDH1A1L3MBTL1NPC1MAPTMAPK1
SCHEMBL17762744 0.86 MAPT (0.53) ALDH1A1L3MBTL1NPC1MAPTMAPK1
SCHEMBL23185880 0.86 ALDH1A1 (0.56) ALDH1A1L3MBTL1NPC1MAPTMAPK1
SCHEMBL30915072 0.85 ALDH1A1 (0.57) ALDH1A1L3MBTL1NPC1MAPTMAPK1
SCHEMBL31737239 0.85 ALDH1A1 (0.55) ALDH1A1L3MBTL1NPC1MAPTMAPK1
SCHEMBL3774389 0.85 ALDH1A1 (0.55) ALDH1A1L3MBTL1NPC1MAPTMAPK1
SCHEMBL3776289 0.84 ALDH1A1 (0.54) ALDH1A1L3MBTL1NPC1MAPTMAPK1
SCHEMBL4062890 0.84 GPR119 (0.61) ALDH1A1L3MBTL1NPC1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855194-B2 Pyrimidine, quinazoline, pteridine and triazine derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-21 US disclosed
EP-2001867-B1 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-07-01 EP disclosed
CN-101405284-A Pyrimidine, quinazoline, pteridine and derivatives HOFFMANN LA ROCHE (CH) 2009-04-08 CN disclosed
EP-2001867-A2 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
WO-2007110340-A2 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives SSTR5, SSTR3, SSTR1 ALDH1A1 2891/4885L3MBTL1 4832/4885NPC1 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.